Israel Active

More about Israel’s Avertto (see previously) that has developed the first medical device with an AI alert of an impending stroke based on biological mimicry. Avertto cites studies indicating that 80% of strokes are preventable.

Israel’s MeMed (see previously) successfully completed the first clinical trial of its BV test to differentiate between bacterial and viral infections. The test on 260 patients with suspected lower respiratory tract infection resulted in a 62% relative reduction in unnecessary antibiotics.

Researchers at Tel Aviv University a significant portion of cancer cells are “aneuploid” – i.e. have an abnormal number of chromosomes. It means they are more sensitive to certain anti-cancer treatments. Patients with that type of cancer could respond to these individually targeted treatments.

Israel’s Ananda Labs is developing an organic treatment that improves skin elasticity, diminishing wrinkles and scars. Using technology of Hebrew University Prof. Yossi Buganim, Ananda genetically reprograms skin cells into placental stem cells, up to 50% younger than the adult originals.

BARDA, part of the US department of Health and Human Services’ Administration for Strategic Preparedness and Response, is funding development by Israel’s Redhill of Opaganib (see previously) for the treatment of the Ebola virus.

Israel’s TechnoPulm is developing a handheld device capable of performing full lung function tests. The tool will replace large, expensive machines with a compact, portable device that weighs just 400 grams. It can be operated in the physician's office and complete the entire test in under three minutes.

Italy’s Menarini Diagnostics is to distribute the EpiCheck non-invasive bladder cancer urine test from Israel’s Nucleix (see previously) in Europe. Bladder cancer is the sixth most common cancer as there are approximately 760,000 people in Europe with the disease.

Israeli startups Collplant and Stratasys have commenced a pre-clinical study to test the ability of their 3D-printed implants (see previously) to promote the growth of natural tissue and completely degrade over time. It may be an alternative to reconstructive surgery after cancer surgery.

Israel’s Metabolize is testing two molecules that reduce both appetite and weight, helping to treat diabetics and the obese. The phenylalanine metabolite X-Phe and N-acetyltaurine (NAT) don’t have the side effects of existing medications and can be ingested rather than injected.

The Pioneering Israeli Medicine Conference in New York City (Sep 22) highlighted new technologies, innovating hospitals, physical & mental rehabilitation, innovation in emergency medicine. The lessons learned from Oct 7 helped medical professionals prepare for the escalation with Hezbollah.